V3388
Vascular Endothelial Growth Factor (aa 207-318) human
≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder
别名:
VEGF112, Vasculotropin
Product Name
Vascular Endothelial Growth Factor (aa 207-318) human, ≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder
生物来源
human
质量水平
重组
expressed in E. coli
方案
≥97% (SDS-PAGE)
表单
lyophilized powder
效能
0.75-3.75 ng/mL ED50
分子量
predicted mol wt ~28 kDa
包装
pkg of 5 μg
储存条件
avoid repeated freeze/thaw cycles
杂质
<1 EU/μg
UniProt登记号
储存温度
−20°C
基因信息
human ... VEGFA(7422)
应用
Vascular Endothelial Growth Factor (aa 207-318) human also known as VEGF 121 was used for preparing a cellular matrix hybridized with hyaluronic acid (ACM-HA) VEGF constructs which is used in measuring the VEGF-enhanced tissue-engineered bladder graft neovascularization by using dynamic contrast-enhanced MRI. The product was used for creating VEGF-impregnated tissue-engineered construct which was inserted in the critical-sized calvarial defect in the membranous parietal bone of the rabbit for examining and characterizing the angiogenesis necessary for bone formation.
生化/生理作用
Potent angiogenesis inducer in vivo.
Vascular Endothelial Growth Factor (aa 207-318) human also referred to as VEGF 121 or Vasculotropin is a basic protein that induces endothelial cell growth, vasculogenesis and angiogenesis. VEGF also enhances the growth of endothelial cells isolated from cerebral cortex, fetal and adult aorta as well as human umbilical vein. Cells enhance VEGF 121 secretion from fibrin implants results in local and controlled blood vessel growth.
外形
Lyophilized from a 0.2 μm filtered solution in 30% acetronitrile and 0.1% TFA containing 0.25 mg bovine serum albumin.
分析说明
The biological activity is measured by its ability to stimulate 3H-thymidine incorporation in human umbilical vein endothelial cells.
其他说明
112 amino acid residue variant of human VEGF.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
Marine Beaumont et al.
NMR in biomedicine, 23(1), 48-55 (2009-08-04)
Tissue engineering is a promising technique for bone repair and can overcome the major drawbacks of conventional autogenous bone grafting. In this in vivo longitudinal study, we proposed a new tissue-engineering paradigm: inserting a biological soft-tissue construct within the bone
Leung, D.W., et al.
Science, 246 (1989)
Lisa Cartwright et al.
Journal of biomedical materials research. Part A, 77(2), 390-395 (2006-01-24)
Tissue engineered organs require an immediately perfused vascular tree. Currently, neovascularization assessment requires animal sacrifice and graft harvest. In this pilot study we assess whether neovascularization of an engineered urinary bladder construct is enhanced with vascular-derived endothelial growth factor (VEGF)
Sevan Evren et al.
Cells, tissues, organs, 192(4), 250-261 (2010-07-01)
Natural scaffolds have been shown to induce T helper 2 (TH2)-specific immune responses in host tissues; however, the precise mechanisms that underlie this immune response are unknown. Using a porcine animal model, we evaluated the role of Toll-like receptors (TLRs)
Martin Ehrbar et al.
Circulation research, 94(8), 1124-1132 (2004-03-27)
Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF
商品
VEGF-A stimulates blood vessel growth via endothelial cell proliferation, migration, and survival during embryonic development.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持